

**POSITION TITLES:** Distinguished Professor and Chairman, Department of Ophthalmology, University of Pittsburgh School of Medicine, The Eye and Ear Foundation Endowed Chair, Director of the UPMC and UPSOM Vision Institute; Executive Vice President of UPMC Enterprises; Emeritus Professor, Sorbonne University, Paris, France;

---

**EDUCATION/TRAINING**

INSTITUTION AND LOCATION	DEGREE	COMPLETION DATE	FIELD OF STUDY
Paris University Medical School, Paris, France	Medical Degree	12/1980	Medicine
Rothschild Ophthalmology Foundation, Paris, France	Residency	10/1979 -09/1980	Ophthalmology
Louis Pasteur University Hospital, Strasbourg, France	Residency	10/1980-03/1984	Neurology, Neurosurgery, Ophthalmology
French National Certifying Board	Ophthalmology	04/1984	Ophthalmology
Louis Pasteur University Hospital, Strasbourg, France	Clinical Fellow Chef de Clinique des Universités	04/1984-03/1988	Ophthalmology
Massachusetts Eye and Ear Infirmary, Harvard Medical School, Boston, Massachusetts	Research Fellow	10/1986-09/1987	Ophthalmology (Prof. D. M. Albert)
Harvard Biological Laboratories, Department of Cellular and Developmental Biology, Harvard University, Cambridge, Massachusetts	Visiting Scholar	02/1987-09/1987	Biology (Prof. J. E. Dowling)

**A. Personal Statement**

The primary focus of my laboratory and clinical investigations is to understand the mechanisms associated with retinal degeneration in order to develop vision restoration therapies. Together with my collaborators I have been working on i) the conception, development, and evaluation of innovative treatments for retinal diseases, with a special focus on genetic rod-cone dystrophies and age-related retinal degenerations; ii) translation to the clinic of sight saving approaches, including neuroprotection, stem cells, gene therapy and optogenetics, pharmacology, and visual prostheses.

I led several first-in-man vision restoration clinical trials (Gene Therapy, Retinal Prosthesis, Optogenetics). I founded and directed (from 2008 to 2020) the Institut de la Vision in Paris, a site for translational research on treatments for currently untreatable inherited and age-related ocular diseases that comprises 18 principal investigators and more than 300 members, and functions in synergy with the Quinze-Vingts National Eye Hospital and the Clinical Investigation Center, overseeing more than 80 clinical trials, some of them within the most advanced areas of biomedical technologies worldwide, such as retinal implants and gene therapy, including several first-in-human trials. In 2016, I was appointed Professor and Chairman of the Department of Ophthalmology at the University of Pittsburgh Medical School, and The Eye and Ear Foundation Endowed Chair. I am actively expanding the Department of Ophthalmology at the University of Pittsburgh (now more than 40 PIs), launching breakthrough trials and developing new models of care around a new translational Vision Institute (400,000 sqf, opened in May 2023). I published more than 800 peer-reviewed articles and co-authored more than 90 patents. I co-founded a dozen start-up companies, including Fovea pharmaceuticals, GenSight Biologics, Pixium Vision, Sparing Vision, SharpEye, VegaVect, Avista, Tilak, Tenpoint, and Netramind.

## B. Positions and Honors

### *University positions*

1987-1992	Visiting Lecturer in Ophthalmology - Department of Ophthalmology - Harvard Medical School, Boston, Massachusetts, USA
1988-2002	University Professor of Ophthalmology – Strasbourg University (1st class since 1999)
1993-1995	Visiting Professor - Department of Ophthalmology and Visual Sciences, University of Madison/Wisconsin
2001-2017	Cumberlege Chair: Professor of Biomedical Sciences - Institute of Ophthalmology-University College London
2002-2022	University Professor of Ophthalmology – Paris (VI) Pierre and Marie Curie University Medical School, now Sorbonne Université (Exceptional Class since 2010)
2012-2015	Visiting Professor: Hebrew University of Jerusalem, Israel
2015-2016	Invited Professor at Collège de France : Chaire « Innovation Technologique»
Since 2016	Professor and Chairman of the Department of Ophthalmology at the University of Pittsburgh School of Medicine, The Eye and Ear Foundation Endowed Chair (Distinguished Professorship since 2019)
Since 2017	Honorary Professor, University College London
Since 2017	Adjunct Professor of Robotics and Bioengineering, Carnegie Mellon University, Pittsburgh
Since 2019	Adjunct Professor of Ophthalmology, Hebrew University of Jerusalem, Israel
Since 2023	Emeritus Professor of Ophthalmology, Sorbonne Université

### *Hospital positions*

1988-2001	Hospital full time clinician, Ophthalmology-Ophthalmological Clinic–Strasbourg University Hospital
Since 2001	Hospital clinician, Ophthalmology–Quinze-Vingts National Ophthalmology Hospital, Paris
2001-2020	Chairman Department of Ophthalmology–Quinze-Vingts National Ophthalmology Hospital, Paris
	Chairman Department of Ophthalmology and Vitreo-Retinal Diseases–Foundation A. de Rothschild
Since 2016	Chairman Department of Ophthalmology/University of Pittsburgh Medical Center

### *Hospital and university activities*

1988-2002	Director of the Eye Pathology Laboratory -Louis Pasteur University-Strasbourg
-----------	---

1994-2001	Head of the Functional Unit "Retina and Oncology" at Ophthalmology Clinic – Strasbourg University Hospital
2005-2020	Director of the Clinical Investigation Centre –503 INSERM/ Quinze-Vingts National
2005-2019	Director National Reference Centre REFERET for Inherited Retinal Dystrophies
2019-2023	Director Institut Hospitalo-Universitaire FOReSIGHT
2023-	Director of the Vision Institute of Pittsburgh (University of Pittsburgh School of Medicine and Medical center)
2025-	Executive Vice President of UPMC Enterprises
2025-	Chief of the Health Technology Advancement Program (HTAP), UPMC

#### ***Research activities***

1999-2002	Director of INSERM EMI 99-18 – UPRES EA 24-10: Cellular and Molecular Physiopathology of the retina -Louis Pasteur University, Strasbourg
2002-2008	Director of UMR INSERM-UPMC 592: Cellular and Molecular Physiopathology of the Retina, Paris
2003-	Co-founder of European Vision Institute, EEIG
2005-2007	Coordinator of the Vision Research National Program (Inserm).
2005-2008	Scientific director of the Vision Institute project – CHNO des Quinze-Vingts
2006-	Director of the "Seeing and Hearing" Institut Carnot (Vision Institute with Pasteur Institute)
2006-2018	Director of the "Seeing and Hearing" Scientific Cooperation Foundation
2007-2017	Coordinator of the Foundation Fighting Blindness Paris Research Centre
2009-2020	Director of the Research Centre: Vision Institute, UMR S 968 Inserm, UM80 Sorbonne Univ./ UMR 7210 CNRS
2011-2019	Director of the Laboratory of Excellence "LIFESENSES: senses for a lifetime" (22M€ Grant)
2019-2024	Director Institut Hospitalo-Universitaire FOReSIGHT (50M€ Grant)
2016-	Chairman of the University of Pittsburgh School of Medicine Ophthalmology Research Center (Vision Institute of Pittsburgh)

#### **C. Other Experience and Professional Memberships**

2014-	Member of Commission Innovation 2030
2021-	Member of Conseil Stratégique des Industries de Santé
2022-	Director, The Foundation Fighting Blindness Retinal Degeneration Fund
2023-	Vice-President (Strategy): Biocluster Brain and Mind, Paris
2023-	Member Conseil de l'Ordre National du Mérite
2023-	Member of Conseil Présidentiel de la Science, advising Président Emmanuel Macron
2024-	Advisor, LightStone Ventures
2024-	Président du Conseil Scientifique : Institut de Réhabilitation Visuelle Saint-Louis, Paris
2024-	Conseil Scientifique, Institut de la Myopie, Paris
2024-	Co-Chairman: Vision Restoration and Rehabilitation, and Outcome Measures, Collaborative Community of Ophthalmic Innovation (with FDA and NEI)
2024-	Co-Chairman: Ocular Disease Forum 2024- Berkeley
2025-	Executive Vice-President, UPMC Enterprises
2025-	Scientific Council, Essilor Luxottica

***Journal editorial boards:*** Journal of Clinical Investigation; Science Translational Medicine;; Ophthalmology and Therapy

**Journal reviewing:** The Lancet; Science; Nature; Nature Medicine; Nature Biotechnology; Nature Communications; Science Translational Medicine; Journal of Clinical Investigation; Proceedings of the National Academy of Sciences of the United States of America; Progress in Retinal and Eye Research; Investigative Ophthalmology & Visual Science; Restorative Neurology and Neuroscience; Graefe's Archive for Clinical and Experimental Ophthalmology; JAMA Ophthalmology; PLOS Genetics; PLOS ONE; Scientific Reports; Orphanet Journal of Rare Diseases; Experimental Eye Research; Neuroscience & Behavioral Reviews; Retina, The Journal of Retinal and Vitreous Diseases; Translational Vision Science & Technology; Expert Review of Molecular Diagnostics; Ophthalmic Research; Laboratory Investigation

**Extramural grant reviewing:** Foundation Fighting Blindness, US; Neurosciences and Mental Health Board (NMHB), UK; Israel Ministry of Science, Technology and Space, Israel; Deutsche Forschungsgemeinschaft (DFG), Germany; Agence Nationale de la Recherche (ANR), France; Banque publique d'investissement (Bpifrance), France; Fédération des Aveugles de France; Retina France, France; European Research Council (ERC); Israel Science Foundation (ISF), Israel; Medical Research Council, UK; Fondation Recherche Médicale (FRM), France; Fondation Simone et Cino del Duca-Institut de France, France; National Institute for Health Research, UK; European Research Area Networks-Neuron; Fight for Sight, UK; Retinitis Pigmentosa Fighting Blindness, UK; Department of Defense, USA (Chair, 2024); Brain Initiative, NIH, USA

**Awards:** Thesis medal (1980), IPSEN Foundation International Prize (1985), Fondation pour la recherche thérapeutique (1986), Research To Prevent Blindness International Scholar Award (1990), Research Prize of the French Society of Ophthalmology (1990), Prix de parrainage de la Fondation Alsace (1994), Mérite Typhlophilie Gold Medal (Fight against Blindness) (2001), Foundation Bettencourt Schueller 'Coups d'élan pour la Recherche Française' Prize (2002), Knight of the National Order of Merit (2004), Foundation Fighting Blindness (FFB) Trustee Award (2005), Emilia Valori Grand Prix of the French Academy of Sciences (2005), The Institut de France's Foundation NRJ Grand Prix scientifique (2006), Alcon Research Institute Award for Excellence in Vision Research (2006), Elected to the European Academy of Ophthalmology (2006), The Altran Foundation Innovation Award (2007), Quebec Vision Research Network's Prize (Canada) (2007), Elected to the Academia Ophthalmologia Internationalis (2007), Elected to the Academy of Sciences-Institut de France (2007), Gold Medal of the University Pierre et Marie Curie (2008), Knight of the National Order of Legion of Honor (2008), Honoris Causa Doctorate from the University of Geneva (2010), Coscas Medal, Retina (2012), Rome, Jules Gonin lecture, Prize of the of the Retina Research Foundation, Reykjavik (2012), CNRS Medal of Innovation (2012), ARVO Silver Fellow (2013), Prix La Recherche (2013), Officer of the National Order of Merit (France) (2014), Prix Inter-Optiques de la Filière de la Vision (2014), Prix Chaptal of the French Industry (2014), Special Recognition Award Retina International (2014), Elected to the German National Academy of Sciences Leopoldina (2014), Foundation Fighting Blindness (FFB) Llura Liggett Gund Lifetime Achievement Award (2015), Prix Opecst-Inserm (2015), Prix Alfred Monnier (2015), Elected to the National Academy of Technologies of France (2015), Ladies Hospital Aid Society (LHAS) doctor of distinction (2017), Elected Member, The Association of American Physicians (2018), Officer of the National Order of the Legion of Honor (2018), Distinguished Professor at the University of Pittsburgh (2019), Prix Charpak-Dubousset-Académie Nationale de Médecine (with Serge Picaud) (2019), Médaille Grand Vermeil de la Ville de Paris (2019), Dastgheib Pioneer Award in Ocular Innovation-Duke University (2020), Gold Fellow ARVO (2020), Médaille Ambroise Paré-Académie Nationale de Chirurgie (2020), Elected to the National Academy of Surgery of France (2020), Breakthrough of the Year in the Life Sciences category-Falling Walls Foundation, Berlin, Germany (2021), The Chica and Heinz Schaller Foundation Award in Translational Neuroscience (FENS) (2022), Peter Watson Medal-Cambridge University (2022), Elected member of the American Ophthalmology Society (2021, induction in 2022), Commandeur Ordre National du Mérite (2023), Ambroise Paré Medal Award, the National Academy of Surgery (2023), The American Foundation for the Blind Corinne Kirchner Award (2023), The International Prize in Translational Neuroscience-The Reemtsma Stiftung- Max Planck Gesellschaft (with Botond Roska) (2023), Elected Fellow of the National Academy of Inventors (2024), The EURORDIS-Rare Diseases Europe Black Pearl

Scientific Award (2024), The Michaelson Award & Lecture, The Macula Society (2024), The Fishman Award and Lecture (2024), The 2024 Wolf Prize in Medicine, The Wolf Foundation (with Botond Roska) (2024), Future Vision Laureate Award (2025), International Engineering and Technology Institute (IETI) Laureate Distinguished Fellow (2025), Elected to the Academia Europaea-Academy of Europe(2025), Elected Fellow of the Asia-Pacific Artificial Intelligence Association (2025), Proctor Medal and Lecture of ARVO (2026), . Distinguished Innovator Award and lecture, Massachusetts Eye and Ear, Harvard Medical School, (2026).

#### D. Contributions to Science

1. Together with my team, I worked on the conception, development, and evaluation of innovative treatments for retinal diseases -with a special focus on genetic rod-cone dystrophies- including neuroprotection, stem cells, gene therapy, pharmacology, and artificial retina. I was the first to hypothesize and demonstrate that rod photoreceptors produce a protein that rescues cone photoreceptors, thereby maintaining light-adapted and high-resolution vision. We (with S. Mohand-Said and Thierry Leveillard) identified the underlying signal: Rod-derived Cone Viability Factor (RdCVF) and determined its mechanisms of action (stimulation of aerobic glycolysis, and antioxidant).
  - a. Aït-Ali N, Fridlich R, Millet-Puel G, Clérin E, Delalande F, Jaillard C, Blond F, Perrocheau L, Reichman S, Byrne LC, Olivier-Bandini A, Bellalou J, Moyse E, Bouillaud F, Nicol X, Dalkara D, van Dorsselaer A, Sahel JA, Léveillard T. Rod-derived cone viability factor promotes cone survival by stimulating aerobic glycolysis. *Cell*. 2015 May 7;161(4):817-32. PubMed PMID: 25957687.
  - b. Léveillard T, Mohand-Saïd S, Lorentz O, Hicks D, Fintz AC, Clérin E, Simonutti M, Forster V, Cavusoglu N, Chalmel F, Dollé P, Poch O, Lambrou G, Sahel JA. Identification and characterization of rod-derived cone viability factor. *Nat Genet*. 2004 Jul;36(7):755-9. PubMed PMID: 15220920.
  - c. Mohand-Said S, Hicks D, Léveillard T, Picaud S, Porto F, Sahel JA. Rod-cone interactions: developmental and clinical significance. *Prog Retin Eye Res*. 2001 Jul;20(4):451-67. PubMed PMID: 11390256.
  - d. Mohand-Said S, Deudon-Combe A, Hicks D, Simonutti M, Forster V, Fintz AC, Léveillard T, Dreyfus H, Sahel JA. Normal retina releases a diffusible factor stimulating cone survival in the retinal degeneration mouse. *Proc Natl Acad Sci U S A*. 1998 Jul 7;95(14):8357-62. PubMed Central PMCID: PMC20980.
2. RdCVF use is now in translation as a possible therapeutic agent to save cones and treat a spectrum of retinal degenerative diseases as a mutation independent strategy.
  - a. Sahel JA, Bennett J, Roska B. Depicting brighter possibilities for treating blindness. *Sci Transl Med*. 2019 May 29;11(494) PubMed PMID: 31142676.
  - b. Byrne LC, Dalkara D, Luna G, Fisher SK, Clérin E, Sahel JA, Léveillard T, Flannery JG. Viral-mediated RdCVF and RdCVFL expression protects cone and rod photoreceptors in retinal degeneration. *J Clin Invest*. 2015 Jan;125(1):105-16. PubMed Central PMCID: PMC4382269.
  - c. Léveillard T, Sahel JA. Rod-derived cone viability factor for treating blinding diseases: from clinic to redox signaling. *Sci Transl Med*. 2010 Apr 7;2(26):26ps16. PubMed Central PMCID: PMC2896730.
  - d. Yang Y, Mohand-Said S, Danan A, Simonutti M, Fontaine V, Clerin E, Picaud S, Léveillard T, Sahel JA. Functional cone rescue by RdCVF protein in a dominant model of retinitis pigmentosa. *Mol Ther*. 2009 May;17(5):787-95. PubMed Central PMCID: PMC2835133.
3. Utilizing a variety of molecular and functional genomics approaches, my group aims to identify novel disease-causing genes for retinal degenerations. Besides research on developmental biology, functional genomics, physiology and therapeutics, my team (with M.Paques, S. Mohand-Said and I. Audo) conducts research on genotype-phenotype correlations with high resolution *in vivo* non-invasive high-resolution retinal imaging techniques (optical coherence tomography and adaptive

optics) aiming at identifying patients eligible for clinical application of innovative therapies. We have developed a number of regenerative therapeutic approaches to restore vision such as gene therapy (including the first advanced trials on mitochondrial diseases), leading to the first demonstration in several large-scale randomized trials of the efficacy of Gene Therapy in Leber Hereditary Optic Neuropathy.

- a. Yu-Wai-Man P, Newman NJ, Bioussé V, Carelli V, Moster ML, Vignal-Clermont C, Klopstock T, Sadun AA, Sergott RC, Hage R, Degli Esposti S, La Morgia C, Priglinger C, Karanja R, Taiel M, Sahel JA. Five-Year Outcomes of Lenadogene Nolparvovec Gene Therapy in Leber Hereditary Optic Neuropathy. *JAMA Ophthalmol.* 2025 Feb 1;143(2):99-108. PubMed PMID: 36999886.
- b. Sahel JA, Grieve K, Pagot C, Authié C, Mohand-Said S, Paques M, Audo I, Becker K, Chaumet-Riffaud AE, Azoulay L, Gutman E, Léveillard T, Zeitz C, Picaud S, Dalkara D, Marazova K. Assessing Photoreceptor Status in Retinal Dystrophies: From High-Resolution Imaging to Functional Vision. *Am J Ophthalmol.* 2021 Oct;230:12-47. PubMed Central PMCID: PMC8682761.
- c. Newman NJ, Yu-Wai-Man P, Carelli V, Moster ML, Bioussé V, Vignal-Clermont C, Sergott RC, Klopstock T, Sadun AA, Barboni P, DeBusk AA, Girmens JF, Rudolph G, Karanja R, Taiel M, Blouin L, Smits G, Katz B, Sahel JA. Efficacy and Safety of Intravitreal Gene Therapy for Leber Hereditary Optic Neuropathy Treated within 6 Months of Disease Onset. *Ophthalmology.* 2021 May;128(5):649-660. PubMed PMID: 33451738.
- d. Yu-Wai-Man P, Newman NJ, Carelli V, Moster ML, Bioussé V, Sadun AA, Klopstock T, Vignal-Clermont C, Sergott RC, Rudolph G, La Morgia C, Karanja R, Taiel M, Blouin L, Burguière P, Smits G, Chevalier C, Masonson H, Salermo Y, Katz B, Picaud S, Calkins DJ, Sahel JA. Bilateral visual improvement with unilateral gene therapy injection for Leber hereditary optic neuropathy. *Sci Transl Med.* 2020 Dec 9;12(573) PubMed PMID: 33298565.

4. With B. Roska at the Institute of Ophthalmology of Basel, S.Picaud and Deniz Dalkara at Institut de la Vision in Paris, we demonstrated that different retinal cell types such as "dormant cones" and Ganglion Cells can be converted into "artificial photoreceptors" by targeting the expression of genetically encoded light sensors enabling mice with retinal degeneration to perform visually guided behaviors. I led the first demonstration of the efficacy of Optogenetics in partial function restoration in humans. I also led (with Dr. Palanker) the first in-human wireless artificial retina trial.

- a. Palanker D, Le Mer Y, Mohand-Said S, Sahel J. Simultaneous perception of prosthetic and natural vision in AMD patients. *Nature Communications.* 2022 January 26; 13(1):-. Available from: <https://www.nature.com/articles/s41467-022-28125-x> DOI: 10.1038/s41467-022-28125-x
- b. Sahel J, Boulanger-Scemama E, Pagot C, Arleo A, Galluppi F, Martel J, Esposti S, Delaux A, de Saint Aubert J, de Montleau C, Gutman E, Audo I, Duebel J, Picaud S, Dalkara D, Blouin L, Taiel M, Roska B. Partial recovery of visual function in a blind patient after optogenetic therapy. *Nature Medicine.* 2021 May 24; 27(7):1223-1229. Available from: <https://www.nature.com/articles/s41591-021-01351-4> DOI: 10.1038/s41591-021-01351-4
- c. Palanker D, Le Mer Y, Mohand-Said S, Muqit M, Sahel JA. Photovoltaic Restoration of Central Vision in Atrophic Age-Related Macular Degeneration. *Ophthalmology.* 2020 Aug;127(8):1097-1104. PubMed Central PMCID: PMC7384969.
- d. Roska B, Sahel JA. Restoring vision. *Nature.* 2018 May;557(7705):359-367. PubMed PMID: 29769667.
- e. Holz FG, Le Mer Y, Muqit MMK, Hattenbach LO, Cusumano A, Grisanti S, Kodjikian L, Pileri MA, Matonti F, Souied E, Stanzel BV, Szurman P, Weber M, Bartz-Schmidt KU, Eter N, Delyfer MN, Girmens JF, van Overdam KA, Wolf A, Hornig R, Corazzol M, Brodie F, Olmos de Koo L, Palanker D, Sahel JA. Subretinal Photovoltaic Implant to Restore Vision in Geographic Atrophy Due to AMD. *N Engl J Med.* 2025 Oct 20:10.1056/NEJMoa2501396. doi: 10.1056/NEJMoa2501396. Epub ahead of print. PubMed PMID: 41124203; PubMed Central PMCID: PMC7618305.

## E. Additional Information: Research Support and/or Scholastic Performance

### *Ongoing research support*

2024-2028	ARPA-H: THEA Eye Transplantation : Sub No. 63619542-341318  around 9M\$
2022-2026	NIH/NEI R01 EY033049-01A1: "Retinal-adhesive thermoresponsive gel for AAV-mediated gene delivery to the outer retina" \$2,857,940
2022-2026	Research to Prevent Blindness: Unrestricted Grant (Support research at the University of Pittsburgh Department of Ophthalmology) \$575,000
2020-2025	NEI/NIH: R01EY030517 "Distinguishing normal aging from age-related macular degeneration at the level of single cells in the living human eye" \$2.4M
2021-2025	Grant from the Hillman Foundation (Access to care, innovative vision restoration therapies- \$20M)
2022-2027	UNIRARE Natural History Study in Retinal Degenerations (FFB, 40 centers) Coordinator, \$6M
2023-2025	Foundation for the National Institutes of Health (FNIH): "Quantification of AAV dose-response with single cell resolution" \$575,000 (PI Leah Byrne)
2023-2025	Eye and Ear Foundation/RK Mellon Foundation "Clinical Trial to Test the Efficacy of a Neuroprosthetic to Treat and Cure Blindness" \$300,000
2022-2028	JAEB Center for Health Research Foundation/Foundation Fighting Blindness Consortium # 2870/Uni-Rare "Universal Rare Gene Study: A Registry and Natural History Study of Retinal Dystrophies Associated with Rare Disease-Causing Genetic Variants" \$212,816
2024-2029	NIH/NEI P30 EY008098: Core Grant for Vision Research (co-I; John Ash), \$4M
2025-2027	Pitt Idea Navigation to Commercialization (Pitt. INC), University of Pittsburgh, PI, "Towards High Resolution Vision Restoration by Optogenetic Therapy" \$2,326,086

### *Completed research support*

2005-2009	Coordinator of the Integrated project Functional GENOmic of the RETina-EVI-GENORET, the largest Vision Project funded by EU (FP6- 512036) 10M€; goals: genetic and genomic characterization of retinal diseases; establishment of therapeutic targets for novel strategies to fight blindness
2007-2017	Coordinator of the Foundation Fighting Blindness Paris Research Centre (C-CL-0912-0600-INSERM01; C-GE-0912-0601-INSERM02) 670 000\$; 1,8M\$; goals: characterization of patients with rare retinal diseases, creation of cohorts of patients with genetic and age-related retinal dystrophies
2014-2019	Coordinator of the project "SIGHT AGAIN" (ANR-BPI France) appr. 6M€, role: PI; goals: development of optogenetic and prosthetic approaches for vision restoration
2017-2018	DARPA Grant on CORTICAL SIGHT \$6M, role: PI; goals: studies of neuronal circuitry of visual processing and development of therapeutic strategies for vision restoration at cortical level
2017-2019	Thome Foundation Research Grant on Age-related Macular Degeneration \$500k, role: PI with Ethan Rossi; goals: High resolution imaging and deep phenotyping in age-related macular degeneration.
2014-2020	Coordinator of the European Research Council Synergy Grant "HELMHOLTZ" 13M€, role: PI; goals: developing and implementing in the clinic of high resolution/cell-resolution <i>in vivo</i> non-invasive retinal imaging technologies
2015-2021	Coordinator of the Recherche Hospitalo-Universitaire Program "LIGHT4DEAF": USHER Syndrome 9.5M€, PI
2011-2022	Director Laboratory of Excellence "LIFESENSES: Senses for a Lifetime", Investments in the Future initiative of the French government (ANR-10-LABX-65) 22M €, role: PI; goals: deciphering fundamental mechanisms of vision and hearing loss, development of therapeutic strategies to preserve and rescue vision and audition

2006-2022	Director of Carnot Institute funding (National Agency for Research) 300-800k€/y, role: PI; goals: development of academia-industry partnerships for promoting translational research
2019-2022	Grant from the Richard King Mellon Foundation to the Cortical Sight Project \$6M
2022-2023	Grant from the Jewish Healthcare and Pittsburgh Foundations: a quality process based on Digital Twins. \$400k
2022-2025	DOD-MTEC Grant (selected for funding 2022-2025) : MTEC-22-02-MPAI-001, PI, "Towards High Resolution Vision Restoration by Optogenetic Therapy" \$3M

### ***Organization of International Conferences and Symposia***

April 2002	Consensus Conference (Foundation Fighting Blindness, Inserm, AFM) "Clinical Trials Orphan Retinal Degenerations", Paris, France
April 2005	"Ophthalmic Pan-European Clinical Trials and the Impact of EU Directive" Royal Soc. of Med., London,
July 2007	"Hearing and seeing: Fighting sensory disabilities" Collège de France, Paris, France
Dec 2008	Fondation Singer-Polignac/"Seeing and Hearing" Foundation/Institute of Ophthalmology UCL/Institut de la Vision Symposium "Fighting blinding diseases: towards a joint endeavour" Paris, France
Nov 2009	ESF-UB Conference in Biomedicine in association with Eurovisionnet and Fondation Voir et Entendre "Rare Diseases II: Hearing and sight loss", Sant Feliu de Guixols, Spain
April 2014	Symposium "Stem Cell and Gene Therapy", World Ophthalmology Congress, Tokyo, Japan
April 2014	First French-Japanese Conference "Innovation in Ophthalmology", Tokyo, Japan
June 2014	Symposium "Colors and Art" celebrating Prof. Philippe Lanthony's career, Paris, France
July 2014	Symposium "Cell and Gene Therapy Approaches in Retinal Degenerations", FENS Forum, Milan Italy
Febr 2015	Vision-Innovation Congress, UNESCO Paris, France
April 2016	Vision Research Symposium, Institut de la Vision - Nuffield Laboratory of Ophthalmology, Univ. of Oxford
June 2016	International Symposium « Cortical plasticity in auditory and visual impairment », Collège de France, Paris,
June 2016	International Symposium « Vision restoration: New strategies, new challenges », Collège de France, Paris,
Sept 2016	Second French-Japanese Conference "Innovation in Ophthalmology", Tokyo, Japan
April 2018	French-Japanese Scientific Seminar "Regenerative Medicine for Vision Restoration", Kobe, Japan
May 2019	French American Symposium on Inherited Retinal Dystrophies, Los Angeles, US
Nov 2019	French-Japanese Scientific Seminar "Vision restoration: emerging therapies", Paris, France
Nov 2019	International Conference "10 years of fighting blindness", Paris, France
Nov 2017-2024	Optic nerve Regeneration, the Louis J. Fox Center for Vision Restoration annual meeting, Pittsburgh, PA, USA
Sept 2021	Workshop on Usher 1b Syndrome, Foundation Fighting Blindness
Oct 2021	International Symposium on Usher Syndrome
Sept 2022	The Cambridge Ophthalmology Symposium: The Eye and the Brain, Cambridge, UK
Oct 2022	Joint Symposium University of Pittsburgh-FDA on Outcomes in Bioengineered Implants for the Visual System
Nov 2022	Joint French-Japanese Scientific Seminar 2022 - Vision Restoration: Emerging Therapeutic Approaches, Paris, France
Febr 2024	The Macula Society Meeting The Michaelson Lecture "Gene-Independent Strategies in Retinal Dystrophies: The Translational Pathways" Palm Springs, CA USA
Oct 2025	NF-1 updated and VISION conference, the Louis J. Fox Center for Vision Restoration annual meeting, Pittsburgh, PA, USA

### ***Recent Lectures***

Feb 2023	Glaucoma Research Foundation, Glaucoma 360 12 <sup>th</sup> Annual New Horizons Forum “The future in vision restoration and neuroprotection”, San Francisco, CA, USA
Mar 2023	Pittsburgh Ophthalmology Society, 58 <sup>th</sup> Annual Meeting, “Gene therapy for retinal degenerations and ARMD: promises and challenges”, Pittsburgh, PA, USA
Mar 2023	International Rare Diseases Research Consortium Conference (IRDiRC) and RE(ACT) Congress 2023 “Developing Gene-Independent Approaches for Retinal Dystrophies”, Berlin, Germany
Apr 2023	The Association for Research in Vision and Ophthalmology (ARVO) 2023 Annual Meeting “Bringing gene-independent strategies to the clinic: focus on Optogenetics”, New Orleans, LA, USA
June 2023	Académie Nationale de Chirurgie (The National Academy of Surgery) “Gene therapy and hereditary retinal dystrophy”, Paris, France
Aug 2023	Association for Ocular Pharmacology and Therapeutics XVI Biennial Meeting 2023 (AOPT) Keynote “Gene-independent Strategies in Retinal Degenerations”, Indianapolis, IN, USA
Sept 2023	Byrne Lab Science, 2023 Pittsburgh Gene Therapy Bootcamp Lecture Series invited speaker, “Optogenetics in the clinic”, UPMC Vision Institute, Pittsburgh, PA, USA
Sept 2023	Vanderbilt Eye Institute’s (VEI) Distinguished Lecture Series “Gene-independent strategies in retinal degenerations”
Oct 2023	European Vision & Eye Research (EVER) Board Congress 2023 – the De Laey EVER Keynote Lecture “Cone-directed strategies in retinal degenerations”, Valencia, Spain
Nov 2023	France Science Summit, invited panelist and guest speaker, “Overview of Franco-American Partnerships, highlighting key cooperation tools”, The Embassy of France, Washington, DC, USA
Nov 2023	The University of Pittsburgh School of Medicine, Physician Scientist Training Program (PSTP) Symposium keynote speaker, Pittsburgh, PA, USA
Jan 2024	Monaciano III Symposium, “Stabilizing the IRD therapy business model”, Rome, Italy
Febr 2024	47th Annual Macula Society Meeting – I.C. Michaelson Symposium “Gene-Independent Strategies in Retinal Dystrophies: The Translational Pathways”, Palm Springs, CA, USA
May 2024	2024 Association for Research in Vision and Ophthalmology (ARVO) Annual Meeting invited symposium speaker and moderator, “Neuro-ophthalmology and genetics”, Seattle, WA, USA
May 2024	Kresge Eye Institute – Robert and Gerry Ligon Lecture Symposium “Developing and Accessing Vision Restoration Strategies”
June 2024	Retina International World Congress 2024, joint Retina International and ERN-EYE meeting, 2 <sup>nd</sup> Multi-Stakeholders Meeting on Clinical Trials for Inherited Retinal Diseases – “Challenges for Innovative Treatments: LHON, the challenges of Control groups”, Dublin, Ireland
June 2024	From the Eye to the Brain, Nature Conference “Neuroprotection of Cone Photoreceptors as a Gene-Independent therapeutic strategy in Inherited retinal diseases” Rome, Italy
June 2024	Sculpted Light in the Brain Conference “Sculpting the Future of Vision Restoration” Paris, France
June 2024	Institute of Molecular and Clinical Ophthalmology Basel (IOB) “Translational studies in neuroprotection and vision restoration” Basel, Switzerland
July 2024	Gilbert Family Foundation, Vision Restoration Institute Annual Meeting panelist, “NF1-OPG – Setting preclinical evidence standards for initiating clinical trials”
Aug 2024	33rd Biennial Symposium of the Center for Visual Science Keynote Opening Lecture “Developing Gene-Independent Approaches for Retinal Dystrophies” Rochester, NY USA
Aug 2024	Byrne Lab Science, 2024 Pittsburgh Gene Therapy Bootcamp Lecture Series invited speaker, “Gene Therapy Clinical Trial Endpoints”, UPMC Vision Institute, Pittsburgh, PA, USA
Sept 2024	Military Operational Medicine Research Program Neurosensory Injury Prevention and Treatment IPR Virtual Meeting, “Towards High Resolution Vision Restoration by Optogenetic Therapy”

Sept 2024	Center for Connected Medicine & UPMC Enterprises, Top of Mind Summit: Life Sciences 2024 panelist, “Getting Close & Personal: Strategies for Efficient Trials and Enhanced Patient Engagement”
Sept 2024	2024 i2Eye Conference, “Optogenetics, gene therapy, & vision restoration”, UPMC Vision Institute, Pittsburgh, PA, USA
Oct 2024	2024 Society for Neuroscience Meeting invited speaker and moderator “Miracles Can Happen: Recent Advances in the Restoration of Vision, Hearing, and Touch”, Chicago, IL, USA
Oct 2024	Inserm, “International Joint Labs: a new Inserm initiative to enhance collaborations”
Oct 2024	The Embassy of France, Washington, DC, USA
Oct 2024	It's Possible at Pitt: Life Sciences Series, “Life Sciences Economic Development Approach”, the University of Pittsburgh School of Medicine, Pittsburgh, PA
Nov 2024	The Fichman Lecture: Cone Rescue in Retinal Dystrophies, Jerusalem- Hadassah Hospital and Hebrew University
Dec 2024	Bascom Palmer Eye Institute (BPEI) James V. Bastek, MD Endowed Speaker Series on Hereditary Retinal Disease Research; and “Gene Therapy for Leber Hereditary Optic Neuropathy”, / “Vision Restoration: Prosthetics and Optogenetics”, / “Visual Outcomes in Retinal Degeneration Trials”, Miami, FL, USA
Dec 2024	Optogenetics Symposium – From Scientific Discovery to Medical Application to Societal Impact, “Translational Pathway for Optogenetic Vision restoration” Charité Hospital-Leopoldina Academy, Berlin, Germany
Dec 2024	Humboldt University, (ECN) Optogenetics Speaker Series, “Challenges in Vision Restoration Research”, Berlin, Germany
Dec 2024	Urania-City of Berlin Public Lecture “Is the human dream of restoring sight to blind people coming true?”, Berlin, Germany
Jan 2025	Collaborative Community on Ophthalmic Imaging (CCOI) 2025 Virtual Conference invited speaker, moderator and group leader “From Retinal Prostheses to Optogenetics”
Jan 2025	Collaborative Community on Ophthalmic Imaging (CCOI) 2025 Virtual Conference invited speaker, moderator, group leader and session chair “Vision Assessment and Outcome Measures”
Jan 2025	Keynote Lecture: Gene Therapy for LHON, Optic Nerve Network “Optic Nerve Diseases”, Milan, Italy
Feb 2025	The Macula Society, 48 <sup>th</sup> Annual Metting, “Updated Safety Results from the PIONEER study: Optogenetics for Non-Syndromic Retinitis Pigmentosa”, Charlotte Harbor, FL, USA
Mar 2025	Foundation Fighting Blindness, Clinical Consortium’s Annual Study Group Meeting, “Ongoing Protocol: Uni-Rare Updates + Discussion of Ideas for Analyses, Sub-studies”, Dallas, TX, USA
Mar 2025	New York Medical College (NYMC), Neighborhood Science Seminar Series invited speaker, “From Neuroprotection to Vision Restoration in Retinal Degenerations”, New York, NY, USA
May 2025	12 <sup>th</sup> Annual Minnesota Neuromodulation Symposium, guest speaker, “Optogenetics in human: Partial recovery of visual function in a blind patient”, Minneapolis, MN, USA
May 2025	10 <sup>th</sup> Annual Retinal Therapeutics Innovation Summit, guest speaker, “Optogenetic and Prosthetic Vision Restoration Trials”, Salt Lake City, UT, USA
June 2025	Sorbonne University Faculty of Health Conference, guest speaker, Paris, France
Sept 2025	Future Vision Foundation, 2025 Future Vision Forum: Immunomodulation, Cancer, and Retinal Degeneration/Aging Conference invited speaker and moderator, “Aging/Retinal Degeneration I & II”, Philadelphia, PA, USA
Sept 2025	Duke-Margolis Institute for Health Policy, National Press Club Meeting, Assessing Novel Efficacy Endpoints in Ophthalmologic Rare Disease Drug and Biologics Development, “Key Takeaways and Next Steps for FST and EZ in Interventional Clinical Trials for Rare Diseases” panelist, Washington, DC, USA

Sept 2025	Children's Hospital Philadelphia, 6th Annual Mito Next Generation Therapeutics Panelist, "Primary Mitochondrial Disease and LHON Trials", Philadelphia, PA, USA
Sept 2025	University of Utah, Moran Eye Center, Distinguished Speaker Series invited speaker, "Prosthetic Vision Trials" and "From Neuroprotection to Vision Restoration in Retinal Degenerations", Salt Lake City, UT, USA
Oct 2025	Genetic Counselors - Broadening Research, Insights, and Discussion of Genetic Eye Diseases Conference 2025, Bench to Bedside: Gene Therapy and Clinical Trials in Ocular Genetics invited speaker, "Therapeutic Timing: Gene Therapy Decisions Guided by Disease Progression", Pittsburgh, PA, USA
Nov 2025	Hadassah Eye & Vision Innovation Forum invited speaker and moderator, "Optogenetics, clinical outcomes and new developments", Jerusalem, Israel
Nov 2025	Cosmos Club Wellness Committee invited speaker, "The Future of Vision Restoration" Washington, DC, USA

### ***Recent Webinars/Podcasts***

June 2023	Association for Research in Vision and Ophthalmology (ARVO) SIG invited speaker and panelist, "PRPH2-related retinal disease: A discussion of current clinical observations and basic science towards the development of effective therapies"
Feb 2024	Foundation Fighting Blindness (FFB), Eye on the Cure Podcast – Episode 61
June 2024	The Eye & Ear Foundation of Pittsburgh, Sight + Sound Bites: Seeing the Future of Gene Therapy panelist, "Genetics and Gene Therapy Options"
Sept 2024	Del Monte Institute for Neuroscience Podcast, "Neuroscience Prospectives: How One Doctor is Revolutionizing Vision Loss", the University of Rochester, Rochester, NY, USA
Nov 2024	FOReSIGHT Academy: when Research and Clinical meet The Gene Therapy Revolution, "Gene-independent gene therapies: optogenetics and RdCVF"
April 2025	The Eye & Ear Foundation of Pittsburgh, Sight + Sound Bites: Optogenetics panelist, "Optogenetics"
Aug 2025	The Eye & Ear Foundation of Pittsburgh, Sight + Sound Bites: Inherited Retinal Conditions panelist

### **More than 90 patents**

### **Publications (More than 800 peer-reviewed articles)**

<https://www.ncbi.nlm.nih.gov/myncbi/1BUauHP0QUhAh/bibliography/public/>

Selected 10:

1. Léveillard T, Mohand-Saïd S, Lorentz O, Hicks D, Fintz AC, Clérin E, Simonutti M, Forster V, Cavusoglu N, Chalmel F, Dollé P, Poch O, Lambrou G, **Sahel JA**. Identification and characterization of rod-derived cone viability factor. *Nat Genet*. 2004 Jul;36(7):755-9. doi: 10.1038/ng1386. Epub 2004 Jun 27. PMID: 15220920. <https://pubmed.ncbi.nlm.nih.gov/15220920/>
2. Aït-Ali N, Fridlich R, Millet-Puel G, Clérin E, Delalande F, Jaillard C, Blond F, Perrocheau L, Reichman S, Byrne LC, Olivier-Bondini A, Bellalou J, Moyse E, Bouillaud F, Nicol X, Dalkara D, van Dorsselaer A, **Sahel JA**, Léveillard T. Rod-derived cone viability factor promotes cone survival by stimulating aerobic glycolysis. *Cell*. 2015 May 7;161(4):817-32. doi: 10.1016/j.cell.2015.03.023. PMID: 25957687. <https://pubmed.ncbi.nlm.nih.gov/25957687/>
3. Roska B, **Sahel JA**. Restoring vision. *Nature*. 2018 May;557(7705):359-367. doi: 10.1038/s41586-018-0076-4. Epub 2018 May 16. PMID: 29769667. <https://pubmed.ncbi.nlm.nih.gov/29769667/>

4. **Sahel JA**, Bennett J, Roska B. Depicting brighter possibilities for treating blindness. *Sci Transl Med.* 2019 May 29;11(494):eaax2324. doi: 10.1126/scitranslmed.aax2324. PMID: 31142676. <https://pubmed.ncbi.nlm.nih.gov/31142676/>
5. Yu-Wai-Man P, Newman NJ, Carelli V, Moster ML, Bioussse V, Sadun AA, Klopstock T, Vignal-Clermont C, Sergott RC, Rudolph G, La Morgia C, Karanja R, Taiel M, Blouin L, Burguière P, Smits G, Chevalier C, Masonson H, Salermo Y, Katz B, Picaud S, Calkins DJ, **Sahel JA**. Bilateral visual improvement with unilateral gene therapy injection for Leber hereditary optic neuropathy. *Sci Transl Med.* 2020 Dec 9;12(573):eaaz7423. doi: 10.1126/scitranslmed.aaz7423. PMID: 33298565. <https://pubmed.ncbi.nlm.nih.gov/33298565/>
6. **Sahel JA**, Boulanger-Scemama E, Pagot C, Arleo A, Galluppi F, Martel JN, Esposti SD, Delaux A, de Saint Aubert JB, de Montleau C, Gutman E, Audo I, Duebel J, Picaud S, Dalkara D, Blouin L, Taiel M, Roska B. Partial recovery of visual function in a blind patient after optogenetic therapy. *Nat Med.* 2021 Jul;27(7):1223-1229. doi: 10.1038/s41591-021-01351-4. Epub 2021 May 24. PMID: 34031601. <https://pubmed.ncbi.nlm.nih.gov/34031601/>
7. Nancy J Newman, Patrick Yu-Wai-Man, Prem S Subramanian, Mark L Moster, An-Guor Wang, Sean P Donahue, Bart P Leroy, Valerio Carelli, Valerie Bioussse, Catherine Vignal-Clermont, Robert C Sergott, Alfredo A Sadun, Gema Rebolleda Fernández, Bart K Chwalisz, Rudrani Banik, Fabienne Bazin, Michel Roux, Eric D Cox, Magali Taiel, **José-Alain Sahel**, the LHON REFLECT Study Group, Randomized trial of bilateral gene therapy injection for m.11778G>A MT-ND4 Leber optic neuropathy, *Brain*, 2022; awac421, <https://doi.org/10.1093/brain/awac421>
8. Palanker D, Le Mer Y, Mohand-Said S, **Sahel JA**. Simultaneous perception of prosthetic and natural vision in AMD patients. *Nat Commun.* 2022 Jan 26;13(1):513. doi: 10.1038/s41467-022-28125-x. PMID: 35082313; PMCID: PMC8792035. <https://pubmed.ncbi.nlm.nih.gov/35082313/>
9. Authié CN, Poujade M, Talebi A, Defer A, Zenouda A, Coen C, Mohand-Said S, Chaumet-Riffaud P, Audo I, **Sahel JA**. Development and Validation of a Novel Mobility Test for Rod-Cone Dystrophies: From Reality to Virtual Reality. *Am J Ophthalmol.* 2024 Feb;258:43-54. doi: 10.1016/j.ajo.2023.06.028. Epub 2023 Jul 16. PMID: 37437832. <https://pubmed.ncbi.nlm.nih.gov/37437832/>
10. Holz FG, Le Mer Y, Muqit MMK, Hattenbach LO, Cusumano A, Grisanti S, Kodjikian L, Pileri MA, Matonti F, Souied E, Stanzel BV, Szurman P, Weber M, Bartz-Schmidt KU, Eter N, Delyfer MN, Girmens JF, van Overdam KA, Wolf A, Hornig R, Corazzol M, Brodie F, Olmos de Koo L, Palanker D, **Sahel JA**. Subretinal Photovoltaic Implant to Restore Vision in Geographic Atrophy Due to AMD. *N Engl J Med.* 2025 Oct 20:10.1056/NEJMoa2501396. doi: 10.1056/NEJMoa2501396. Epub ahead of print. PMID: 41124203; PMCID: PMC7618305. <https://pubmed.ncbi.nlm.nih.gov/41124203/>